Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papilledema | 1 | 2023 | 44 | 0.750 |
Why?
|
| Meningioma | 1 | 2023 | 87 | 0.720 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 138 | 0.690 |
Why?
|
| Tomography, Optical Coherence | 7 | 2026 | 271 | 0.600 |
Why?
|
| Macula Lutea | 2 | 2026 | 21 | 0.460 |
Why?
|
| Retinal Diseases | 2 | 2026 | 101 | 0.430 |
Why?
|
| Fluorescein Angiography | 5 | 2026 | 189 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3869 | 0.320 |
Why?
|
| Visual Acuity | 3 | 2026 | 489 | 0.280 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2026 | 2 | 0.240 |
Why?
|
| Triamcinolone Acetonide | 1 | 2026 | 20 | 0.240 |
Why?
|
| Retinal Neovascularization | 1 | 2026 | 29 | 0.230 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2025 | 38 | 0.230 |
Why?
|
| Macular Edema | 1 | 2026 | 49 | 0.230 |
Why?
|
| Wet Macular Degeneration | 1 | 2026 | 58 | 0.220 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2025 | 73 | 0.220 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.200 |
Why?
|
| Neuromuscular Diseases | 1 | 2025 | 146 | 0.200 |
Why?
|
| Optic Nerve | 1 | 2023 | 67 | 0.190 |
Why?
|
| Vitreous Detachment | 1 | 2022 | 6 | 0.190 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2022 | 15 | 0.190 |
Why?
|
| Retinal Vein Occlusion | 1 | 2022 | 14 | 0.180 |
Why?
|
| Retinal Vein | 1 | 2022 | 14 | 0.180 |
Why?
|
| Meningeal Neoplasms | 1 | 2023 | 94 | 0.180 |
Why?
|
| Retinal Detachment | 1 | 2022 | 73 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2026 | 535 | 0.170 |
Why?
|
| Models, Educational | 1 | 2019 | 89 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 970 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2023 | 1495 | 0.140 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 111 | 0.140 |
Why?
|
| Trust | 1 | 2019 | 153 | 0.130 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 207 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2019 | 303 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2023 | 1504 | 0.110 |
Why?
|
| Students, Medical | 1 | 2019 | 375 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 2197 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2019 | 1671 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2026 | 17101 | 0.090 |
Why?
|
| Humans | 9 | 2026 | 144957 | 0.060 |
Why?
|
| Fundus Oculi | 1 | 2026 | 89 | 0.060 |
Why?
|
| Choroid | 1 | 2026 | 80 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 201 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2026 | 237 | 0.050 |
Why?
|
| Intraocular Pressure | 1 | 2026 | 328 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2026 | 261 | 0.050 |
Why?
|
| Scleral Buckling | 1 | 2022 | 16 | 0.050 |
Why?
|
| Vitrectomy | 1 | 2022 | 73 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2022 | 117 | 0.040 |
Why?
|
| Aged | 3 | 2026 | 25947 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2025 | 349 | 0.040 |
Why?
|
| Middle Aged | 4 | 2026 | 35928 | 0.040 |
Why?
|
| Adult | 4 | 2026 | 40506 | 0.040 |
Why?
|
| Male | 5 | 2026 | 72406 | 0.040 |
Why?
|
| Retina | 1 | 2022 | 324 | 0.040 |
Why?
|
| Female | 5 | 2026 | 78376 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2025 | 931 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 326 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 5417 | 0.030 |
Why?
|
| Learning | 1 | 2019 | 452 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 588 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2026 | 8279 | 0.020 |
Why?
|
| Curriculum | 1 | 2019 | 1060 | 0.020 |
Why?
|
| Infant | 1 | 2025 | 10039 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 11695 | 0.020 |
Why?
|